Biogen Pharmachem Announces First Bonus Share Payout in Over Two Decades

Biogen Pharmachem Industries has approved a bonus share issue, offering one new equity share for every six currently held. The record date for determining shareholder eligibility is May 15, 2026.

Key Details of the Bonus Issue

The company's board has also greenlit an increase in authorized share capital from ₹91 crore to ₹108 crore to support this move. The bonus issuance requires shareholder approval, which is being sought through a postal ballot process that includes e-voting. M/s. Goenka Mehta & Associates have been appointed as the new statutory auditors.

What a Bonus Issue Means for Investors

A bonus issue allows companies to reward shareholders by distributing additional shares for free, typically using retained earnings or reserves. This action can increase the total number of shares outstanding, potentially leading to improved market liquidity. While it can signal management confidence and financial strength, a bonus issue does not immediately alter the intrinsic value of a shareholder's investment or their percentage of ownership.

Company Background and Recent Performance

Established in 1995 and based in Rajkot, Gujarat, Biogen Pharmachem Industries (formerly Sun Techno Overseas Limited) operates in share and securities trading, investment banking, and brokerage. Significantly, this 1:6 bonus share issuance is the company's first since at least January 2000. Recent financial results show a net profit of ₹1.34 crore for the quarter ending December 2025, indicating a partial recovery after reporting a net loss for the fiscal year ending March 2025.

Impact on Shareholders

Following the bonus issue, shareholders will see their total share count increase according to the 1:6 ratio. The face value of each bonus share is ₹1. Earnings Per Share (EPS) may become diluted if company profits do not grow proportionally with the increased number of shares. Immediately after the issue, the company's market capitalization is expected to remain unchanged, though the stock price will likely adjust downwards to reflect the larger share count.

Financial Challenges and Risks

Despite the positive development of a bonus issue, Biogen Pharmachem faces significant financial challenges. The company's return on equity (ROE) has been low, averaging 0.78% over the last three years. Management of short-term finances appears strained, with working capital days significantly increasing from 67.5 to 170 days. Furthermore, the company's revenue experienced a compounded annual growth rate (CAGR) of -50% in the last year, and it reported a negative annual net profit for the fiscal year ending March 2025.

Industry Peers

Biogen Pharmachem operates within the financial services sector. Competitors in this space include well-established firms such as Cholamandalam Investment & Finance Company Ltd., Bajaj Finserv Ltd., Shriram Finance Ltd., and Bridge Securities Ltd. Historically, Biogen Pharmachem has generated lower returns compared to many of these peers.

Key Metrics at a Glance

• Revenue CAGR (last year ending March 31, 2025): -50% (Standalone)
• Working Capital Days: Increased from 67.5 to 170 (last reported periods, Standalone)
• Return on Equity (ROE) (last 3 years): 0.78% (Standalone)

What to Watch Next

Investors will be closely monitoring the outcome of the shareholder approval vote. The market's reaction to the bonus announcement and its impact on the stock price will also be key. Future financial performance, particularly revenue growth and profitability, will be critical indicators, especially in light of recent trends and the company's expanded share capital.